11th Monthly Progress Meeting Minutes (05/11/2024)

1. **WP2**:
	* The sequence for p-tau 217 was circulated inside the consortium and verified.
	* GRAPHEAL will visit the Shanghai company on the 15th of November, to discuss provision of p-tau 217 proteins (full protein and peptides). GRAPHEAL will present the 2D-BioPAD project to the Shanghai company. Q-PLAN to send 2D-BioPAD presentation to GRAPHEAL by the 8th of November.
	* NOVA will provide information to ICN2, if it is possible to identify the binding site location following their (ICN2) strategies, by early December.
	* NOVA will try to identify and share with CeADAR data for binding location of proteins other than thrombin. CeADAR will develop an AI/ML model for binding site identification. First results are expected by the end of December.
	* T2.3: AUTH will evaluate MNP conjugation with Thrombin aptamer by the end of November under complex environments.
	* AUTH will evaluate MNP conjugation with the truncated GFAP aptamer, results are expected by the end of January 2024.
	* GRAPHEAL could use MNP from AUTH to amplify sensing, to be confirmed by the end of January 2025.
2. **WP3**:
	* GRAPHEAL will work on GFAP towards the GFET sensor development. Results on GFAP are expected by the end of December 2024. Preliminary results on NfL with GFET biosensor are expected by the end of January 2025.
	* ICN2 will purchase the truncated aptamers for GFAP by the mid of December. Results of the electrochemical biosensing w/ GFAP are expected by the end of February.
	* ICN2 will buy antibodies for Aβ by the 15th of November, to explore their application in LFA. ICN2 will try to use the existing strategy (as designed for aptamers) to identify whether it can be used for antibodies as well.
	* ICN2 & GRAPHEAL will confirm Biosafety Level 2 clearance by the end of December.

1. **WP4** (T4.2):
	* GRAPHEAL to organise a meeting in November to discuss expectation and contributions. Doodle shared [here](https://doodle.com/meeting/participate/id/e9O0543b), for partners to provide their availability.
		+ The meeting has been booked for the 2nd of December at 14:00 CET.
	* GRAPHEAL to update the Action List for WP4 [here](https://upolomouc.sharepoint.com/%3Ax%3A/r/sites/2D-BioPAD/Sdilene%20dokumenty/General/03.Meetings/1.%20Monthly%20Meetings/11_Meeting%2020241105/2D-BioPAD_Action_List_events_20241105_v0.1.xlsx?d=w3ae4937cc0cb4374971fb60c47ede56e&csf=1&web=1&e=Iu79ce) with specific action points and deadlines after the meeting.
2. **WP5** (T5.1):
	* **Results of the German Ethical Committee decision expected by the end of November 2024. ΖΙ to inform about approval status for both the retrospective and prospective clinical pilot study documents by the end of November 2024.**
	* EVNIA and UEF will have a meeting about the regulatory aspects of the clinical protocol **by the end of November**.No need to prepare a regulatory compliant protocol yet.
		+ The meeting has been booked for the 22nd of November at 13:00 CET.
3. **WP6**:
	* T6.1: Partners to promote the project in their events and share material (including photos) with Q-PLAN to enhance project communication. For upcoming events: Partners are requested to **update the events tab in the action list** [**here**](https://upolomouc.sharepoint.com/%3Ax%3A/r/sites/2D-BioPAD/Sdilene%20dokumenty/General/03.Meetings/1.%20Monthly%20Meetings/11_Meeting%2020241105/2D-BioPAD_Action_List_events_20241105_v0.1.xlsx?d=w3ae4937cc0cb4374971fb60c47ede56e&csf=1&web=1&e=FiBVlQ).
	* T6.2: Q-PLAN will commence the interviews about results’ exploitation with UP-CATRIN early in December. The rest of the partners will follow.
	* T6.4: EVNIA will organise a regulatory workshop online. To discuss with the GF Working Group of Dissemination & Communication.
	* T6.5: Q-PLAN will provide updates on the synergies in the next monthly meeting (Teams link [here](https://teams.microsoft.com/l/meetup-join/19%3Ameeting_Mzk4ZDI2MGQtMGZhNS00ZGRmLWI3MWEtNjI3MDcyZDlhMWQ5%40thread.v2/0?context=%7b%22Tid%22%3a%220792fd97-b4b9-4f63-9459-1be9d4004149%22%2c%22Oid%22%3a%2225851c07-8567-4ccd-8227-db51957531f7%22%7d)), on the 6th of December 2024.
4. **WP7**:
	* T7.4: **All partners** to **fill the financial report template and send to UP-CATRIN by the 8th of November.**
	* T7.4: NOVA will discuss internally the possibility of the next project meeting in Bordeaux in March 2025. Q-PLAN and UP-CATRIN to support the organization of the meeting in November/ December 2024.
	* T7.4: Q-PLAN will follow up with specific requests for finalizing the M1-M12 activity report within November.